CN111118112A - 一种高通量基因表达谱检测试剂盒 - Google Patents

一种高通量基因表达谱检测试剂盒 Download PDF

Info

Publication number
CN111118112A
CN111118112A CN201811280846.XA CN201811280846A CN111118112A CN 111118112 A CN111118112 A CN 111118112A CN 201811280846 A CN201811280846 A CN 201811280846A CN 111118112 A CN111118112 A CN 111118112A
Authority
CN
China
Prior art keywords
seq
seqid
gene expression
double
mix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811280846.XA
Other languages
English (en)
Inventor
欧阳宏伟
吴兵兵
李余
邹晓晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CN201811280846.XA priority Critical patent/CN111118112A/zh
Publication of CN111118112A publication Critical patent/CN111118112A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

本发明提供一种高通量基因表达谱检测试剂盒，该试剂盒包括逆转录反应模块、双链cDNA合成模块、核酸纯化模块、测序文库构建模块等4个模块的试剂。本发明提供的试剂盒具有低起始量、高通量、低成本等特点，能广泛应用于药物、生物材料等物理化学生物因素对体外细胞、体内组织、甚至个体的全基因表达谱的系统性检测。

Description

一种高通量基因表达谱检测试剂盒
技术领域
本发明涉及一种高通量基因表达谱检测试剂盒及使用方法，适用于任何具有细胞基因表达水平检测需求的样本，涵盖任何真核生物的细胞。属于生物医学领域。
背景技术
核酸是遗传信息的载体，是最重要的生物信息分子，是分子生物学研究的主要对象。随着精准医疗计划的进展，高通量基因测序技术将在以后的疾病精确诊断、疾病亚型分类、精准监控疾病发生发展、精准指导用药、特异疾病相关基因组数据库建立等方面发挥越来越关键作用。高通量测序的实现离不开样本的收集及测序前样本准备工作。尽管样本从收集到建库的成本显著降低，然而一旦涉及高通量、大量样本的建库，成本依然较高。目前商品化的转录组文库构建试剂盒几乎为进口试剂盒，价格昂贵，且试剂盒中各种成分相对独立，操作繁琐。因此，本发明提供了一种高通量基因表达谱检测试剂盒及使用方法，将整个样本建库前的所有处理步骤模块化，实现了样本处理的简易化、低起始量化、低成本化、高通量化。
发明内容
本发明的试剂盒主要用于高通量的基因表达谱的检测，该检测试剂盒提供了从样本收集到mRNA测序前的所有实验步骤所需的试剂及实验方法；一共可分为四个部分：1. 逆转录反应模块，核酸纯化模块，双链cDNA合成模块，测序文库构建模块。
本发明采用的技术方案为：
一种高通量基因表达谱检测试剂盒，该试剂盒包括逆转录反应模块、核酸纯化模块、双链cDNA合成模块、测序文库构建模块；
该逆转录反应模块，包括细胞裂解液、逆转录Mix、Barcode板(即逆转录引物板)、备用96孔板；其中：
该逆转录反应模块，包括细胞裂解液、逆转录Mix、Barcode板、备用96孔板；其中：
细胞裂解液：用pBS配置的0.3％Triton-100；
逆转录Mix：0.5μl dNTP,0.25μl逆转录酶,1μl 5×逆转录酶Buffer[250mM Tris-HCl(pH 8.3),375mM KCl,15mM MgCl2],0.125μl DTT,0.125μl RNA酶抑制剂,1μl betaine(5M),0.045μl MgCl2；
Barcode板：含96种不同标签的逆转录引物(浓度为20μM)：(5’—3’)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTCACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:1) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACTGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:2) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCAGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:3) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGACTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:4) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:5) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:6) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:7) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTAGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:8) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:9) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGCTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:10)ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ IDNO:11) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCATCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:12) ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:13) ACACTCTTTCCCTACACGACGCTCTTCCGATCTACGTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:14) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:15) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTAGTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:16) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGCATCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:17) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATCTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:18) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGATCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:19) ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:20) ACACTCTTTCCCTACACGACGCTCTTCCGATCTACTCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:21) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCACGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:22) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTCTACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:23) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTCAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:24) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCAGACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:25) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGACTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:26) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:27) ACACTCTTTCCCTACACGACGCTCTTCCGATCTACACTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:28) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:29) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ IDNO:30) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGTCGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:31) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGACGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:32) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGATGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:33) ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGATCGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:34) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACGAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:35) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTAGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:36) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTACGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:37) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:38) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:39) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGCTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:40) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTCACAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:41) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACTGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:42) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCAGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:43) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGACTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:44) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTCAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:45) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTCGAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:46) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGCACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:47) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTAGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ IDNO:48) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACGTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:49) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGCTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:50) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTACAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:51) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCATCTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:52) ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:53) ACACTCTTTCCCTACACGACGCTCTTCCGATCTACGTCAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:54) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATGCTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:55) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTAGTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:56)ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGCATCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ IDNO:57) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATCTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:58) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGATCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:59) ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCACTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:60) ACACTCTTTCCCTACACGACGCTCTTCCGATCTACTCGAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:61) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCACGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:62) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTCTACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:63) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTCAGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:64) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCAGACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:65)ACACTCTTTCCCTACACGACGCTCTTCCGATCTGACTCAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ IDNO:66) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACAGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:67) ACACTCTTTCCCTACACGACGCTCTTCCGATCTACACTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:68) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAGTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:69) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTGATATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:70) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGTCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:71) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGACGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:72) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGATGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:73) ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGATCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:74)ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACGAGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ IDNO:75) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTAGAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:76) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTACGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:77) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCGTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:78) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCATATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:79) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGCTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:80) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCAGACGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:81) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGACTCAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:82) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACAGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:83)ACACTCTTTCCCTACACGACGCTCTTCCGATCTACACTGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ IDNO:84) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAGTAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:85) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTGATGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:86) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGTCGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:87) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGACGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:88) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGATGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:89) ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGATCGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:90) ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACGAGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:91) ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTAGAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:92)ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTACGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ IDNO:93) ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCGTGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:94) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCATGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:95) ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGCTAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:96)
该核酸纯化模块包括纯化用超顺磁性磁珠；
该双链cDNA合成模块包括：双链合成Buffer(10X)、双链合成Enzyme Mix；
双链合成Buffer(10X):200mM Tris-HCl,120mM(NH4)2SO4,50mM MgCl2,1.6 mM b-NAD,1.9mM dNTPs each,pH 7.4
双链合成Enzyme Mix:6,000units/ml DNA Polymerase I(E.coli)5,000units/ml RNaseH,25,000units/ml E.coli DNA Ligase,10mM Tris-HCl(pH 7.5),50mM KCl,1mM DTT,0.1mM EDTA，50％glycerol；
该测序文库构建模块包括片段化酶Mix、中和Buffer、引物1，引物2、PCR Mix；其中
片段化酶Mix：Nextera XT(Illumina)试剂盒中的Tagment DNA Buffer和Amplification Tagment Mix的混合物；
中和Buffer：Nextera XT(Illumina)试剂盒中的NT Buffer；
引物1:
序列为5’-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACG-3’(SEQ ID NO:97)，浓度为5μM；
引物2，含12种不同标签的引物，浓度为5μM：
5’-CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTCTCGTGGGCTCGG-3’(SEQ ID NO:98)
5’-CAAGCAGAAGACGGCATACGAGATCTAGTACGGTCTCGTGGGCTCGG-3’(SEQ ID NO:99)
5’-CAAGCAGAAGACGGCATACGAGATTTCTGCCTGTCTCGTGGGCTCGG-3’(SEQ ID NO:100)
5’-CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTCTCGTGGGCTCGG-3’(SEQ ID NO:101)
5’-CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTCTCGTGGGCTCGG-3’(SEQ ID NO:102)
5’-CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG-3’(SEQ ID NO:103)
5’-CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTCTCGTGGGCTCGG-3’(SEQ ID NO:104)
5’-CAAGCAGAAGACGGCATACGAGATCCTCTCTGGTCTCGTGGGCTCGG-3’(SEQ ID NO:105)
5’-CAAGCAGAAGACGGCATACGAGATAGCGTAGCGTCTCGTGGGCTCGG-3’(SEQ ID NO:106)
5’-CAAGCAGAAGACGGCATACGAGATCAGCCTCGGTCTCGTGGGCTCGG-3’(SEQ ID NO:107)
5’-CAAGCAGAAGACGGCATACGAGATTGCCTCTTGTCTCGTGGGCTCGG-3’(SEQ ID NO:108)
5’-CAAGCAGAAGACGGCATACGAGATTCCTCTACGTCTCGTGGGCTCGG-3’(SEQ ID NO:109)
PCR Mix：166.5mM KCl，33.3mM Tris-HCl(pH 8.3)，6.66mM MgCl2，1mM dNTP,0.5U高保真DNA Polymerase。
本发明还提供了上述高通量基因表达谱检测试剂盒的使用方法，该方法包括如下步骤：
1)、逆转录反应
(1)、提前将96孔板低温离心机降温到4℃；
(2)当所收集的样本为体内组织或个体，则需用传统的trizol法提取总RNA或直接通过任何商业化RNA提取试剂盒提取RNA，当所收集样本为体外细胞，则向样本中直接加入细胞裂解液对细胞进行裂解；
(3)每个样本取裂解后的样本2ul(RNA总量为1-1000ng)于备用96孔板中，用排枪向每个孔加入0.5ul不同的逆转录引物(即barcode板中引物)。
(3)涡旋震荡混匀，3000rpm,4℃,离心3min,在PCR仪上反应(72℃，3min)后，立即放置在冰上；
(5)每个孔依次加入2.5μl逆转录Mix
(6)涡旋震荡混匀，3000rpm,4℃,离心3min，在PCR仪上反应{42℃,90min；[50℃,2min；42℃,2min]10个循环,70℃,15min；16℃,5min；}
(7)逆转录后，同一组barcode的样本可混合到一个EP管中；
所有步骤均在冰上操作。
2)核酸纯化
(1)涡旋震荡纯化磁珠(提前将纯化磁珠平衡至室温)，将磁珠混匀，并取90％体积的磁珠至逆转录混合产物中，涡旋震荡或使用移液器轻轻吹打至充分混匀；
(2)室温孵育5min；
(3)将EP管短暂离心并置于磁力架上约5min，用于分离磁珠和液体；待溶液澄清后，小心移除上清；
(4)保持EP管置于磁力架上，加入180ul-200ul新鲜配置70％～80％酒精漂洗磁珠，室温孵育30s，小心移除上清；
(5)重复(4)的漂洗步骤，总共漂洗2次；
(6)EP管开盖于空气中干燥5～10分钟至无酒精残留；
(7)加入适量灭菌双蒸水，涡旋振荡或用移液器轻轻吹打使与磁珠充分混匀后，室温孵育2min；
(8)将EP管置于磁力架上静置约5min，待溶液澄清后，小心移除上清至新的EP管中，移除过程中切勿触碰磁珠。
纯化后的样本4℃可储存一周，长期储存需放-20℃，避免反复冻融
3)、双链cDNA合成
(1)取100ng上述混合、纯化后的cDNA样本,依次加入2μl双链合成Buffer，1μl双链合成Enzyme Mix，并加水至20μl体系，涡旋震荡混匀；
(2)3000rpm,4℃,离心3min后,在PCR仪上反应(16℃，2.5h)；
(3)按上述PCR反应产物按照核酸纯化模块步骤将双链合成产物进行纯化
所有步骤均在冰上操作；
4)、测序文库构建
(1)根据Qubit检测的样本浓度，将其稀释至0.5-1ng/μl,取1.25μl，加入3.75μl片段化酶Mix；
(2)涡旋20s，3000g离心5min后，在PCR仪上反应[55℃,10min；10℃,5min]；
(3)等温度降到10℃后，迅速在反应体系中加入1.25μl中和Buffer终止反应；涡旋20s， 3000g离心5min；
(4)在上述反应体系中依次加入：3.75μl PCR Mix，1.25μl的i5端富集引物，(引物1),1.25μl i7端引物(引物2)
(5)涡旋20s，3000g离心2min后，在PCR仪上反应[72℃,3min；95℃,30s；12循环(95℃, 10s；55℃,30s；72℃,60s)；72℃,5min；10℃,5min；]
(6)按上述PCR反应产物按照核酸纯化模块步骤进行纯化；
(7)质检：将纯化后的洗脱产物,用Qubit和Agilent Bioanalyzer2200检测样本中双链 DNA的浓度、碱基序列长度分布情况
所有步骤均在冰上操作，纯化后的样本4℃可储存一周，长期储存需放-20℃，避免反复冻融。
本发明所具有的有益效果：
本发明提供了一种高通量基因表达谱检测试剂盒及使用方法，将整个样本建库前的所有处理步骤模块化，实现了样本处理的简易化、低起始量化、高通量化、低成本化。本发明试剂盒能广泛应用于药物、生物材料等物理化学生物因素对体外细胞、体内组织、甚至个体的全基因表达谱的系统性检测。
附图说明
图1为逆转录反应模块流程图；
图2为核酸纯化模块流程图；
图3为双链cDNA合成模块流程图；
图4为测序文库构建流程图；
图5为文库质检结果图；
图6为体外细胞的高通量基因表达谱检测结果分析图；
图7为体内多组织的高通量基因表达谱检测结果分析图；
图8为单个线虫个体的高通量基因表达谱检测结果分析图。
具体实施方式
下面结合具体实施例对本发明进行进一步描述，但本发明的保护范围并不仅限于此：
实施例1：体外细胞的高通量基因表达谱检测
该实施例的实验目的为用HA纳米材料处理体外培养的hBMSC，Myoblast，HUVEC 三种细胞，用于检测和比较这该材料对这三种细胞的基因表达谱的影响。每种细胞分为两个组：材料处理组和非处理组，每个组设三个重复。总的细胞样本数为18个。
1)收集的细胞样本加入适量细胞裂解液；
2)每个样本取裂解后的样本2ul(RNA总量为1-1000ng)于备用96孔板中，用排枪向每个孔加入0.5ul不同的逆转录引物(即barcode)。
3)涡旋震荡混匀，3000rpm,4℃,离心3min,在PCR仪上反应(72℃，3min)后，立即放置在冰上
4)每个孔依次加入2.5μl逆转录Mix
5)涡旋震荡混匀，3000rpm,4℃,离心3min，在PCR仪上反应{42℃,90min；[50℃,2min； 42℃,2min]10个循环,70℃,15min；16℃,5min；}
6)逆转录后，18个样本混合到一个EP管中。
7)纯化磁珠放置室温后，涡旋震荡纯化磁珠，将磁珠混匀，并取90％体积的磁珠至逆转录混合产物中，涡旋震荡或使用移液器轻轻吹打至充分混匀
8)室温孵育5min
9)将EP管短暂离心并置于磁力架上约5min，用于分离磁珠和液体；待溶液澄清后，小心移除上清
10)保持EP管置于磁力架上，加入180ul-200ul新鲜配置70％～80％酒精漂洗磁珠，室温孵育30s，小心移除上清
11)重复(10)的漂洗步骤，总共漂洗2次
12)EP管开盖，于空气中干燥5～10分钟至无酒精残留
13)加入适量灭菌双蒸水，涡旋振荡或用移液器轻轻吹打使与磁珠充分混匀后，室温孵育2min
14)将EP管置于磁力架上静置约5min，待溶液澄清后，小心移除上清至新的EP管中，移除过程中切勿触碰磁珠
15)纯化后的产物进行Qubit测量浓度。
16)取100ng上述混合、纯化后的cDNA样本,依次加入2μl双链合成Buffer，1μl双链合成Enzyme Mix，并加水至20μl体系，涡旋震荡混匀。
17)3000rpm,4℃,离心3min后,在PCR仪上反应(16℃，2.5h)。
18)将上述PCR反应产物按照核酸纯化模块步骤将双链合成产物进行纯化。
19)根据Qubit检测的样本浓度，将其稀释至0.5-1ng/μl,取1.25μl，加入3.75μl片段化酶Mix
20)涡旋20s，3000g离心5min后，在PCR仪上反应[55℃,10min；10℃,5min],等温度降到10度后，迅速在反应体系中加入1.25μl中和Buffer终止反应。涡旋20s，3000g离心5min
21)在上述反应体系中依次加入：3.75μl PCR Mix，1.25μl的i5端富集引物，(引物1),1.25μl i7端引物(引物2)
22)涡旋20s，3000g离心2min后，在PCR仪上反应[72℃,3min；95℃,30s；12循环(95℃, 10s；55℃,30s；72℃,60s)；72℃,5min；10℃,5min；]
23)按上述PCR反应产物按照核酸纯化模块步骤进行纯化
24)质检：将纯化后的洗脱产物,用Qubit和Agilent Bioanalyzer2200检测样本中双链DNA 的浓度、序列长度分布情况，结果显示符合测序上机要求(图5)
25)将高通量测序获得的数据利用R语言进行标准化、差异基因表达及聚类分析，发现同一处理组的重复样本的基因表达谱相似，并且两个比较组在基因表达上确实存在明显的差异(图6)。
实施例2：体内组织的高通量基因表达谱检测
该实施例的实验目的为用羟基磷灰石纳米材料对小鼠进行尾静脉注射，取小鼠心、肝、肾等7种组织和器官进行基因表达谱检测，用于检测和比较这该材料对小鼠体内组织的基因表达谱的影响。小鼠分为两个组：材料处理组和非处理组，每个组设三个重复。总的组织样本数为42个。
收集的42个组织样本用传统Trizol法提取总RNA，逆转录，核酸纯化，双链合成和文库构建步骤同上述18个体外细胞样本的方法。
该42个样本构建的文库进行高通量测序，获得的数据利用R语言进行标准化、差异基因表达及聚类分析，发现每一中组织与其它组织相比，组织基因表达谱相似，PCA聚类分析可聚成一类，同时同一组织的两个比较组之间基因表达上确实存在明显的差异(如图7)
实施例3：个体的高通量基因表达谱检测
该实施例的实验目的为取不同温度处理(变频温度variable组,正常温度control组) 的线虫进行线虫个体水平的基因表达谱检测，用于检测和比较不同温度对线虫基因表达谱的影响。分为两个组：变频温度组和正常温度组，每一条线虫作为一个样本，变频温度组19条，常温组有7条。即总的样本数为26个。
收集的26个组织样本用传统Trizol法提取总RNA，逆转录，核酸纯化，双链合成和文库构建步骤同上述18个体外细胞样本的方法。
将该26条线虫样本构建的文库进行高通量测序，获得的数据利用R语言进行标准化、差异基因表达及聚类分析，发现线虫样本的基因表达谱比较分散，PCA聚类分析没有明显的聚类，但是两个比较组之间基因表达上确实存在明显的差异(如图8)。

Claims (2)

1.一种高通量基因表达谱检测试剂盒，其特征在于：该试剂盒包括逆转录反应模块、核酸纯化模块、双链cDNA合成模块、测序文库构建模块；
该逆转录反应模块，包括细胞裂解液、逆转录Mix、Barcode板、备用96孔板；其中：
细胞裂解液：用pBS配置的0.3％Triton-100；
逆转录Mix：0.5μl dNTP,0.25μl逆转录酶,1μl 5×逆转录酶Buffer[250mM Tris-HCl(pH 8.3),375mM KCl,15mM MgCl2],0.125μl DTT,0.125μl RNA酶抑制剂,1μl betaine(5M),0.045μl MgCl2；
Barcode板：含96种不同标签的逆转录引物(浓度为20μM)：(5’—3’)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTCACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:1)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACTGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:2)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCAGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:3)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGACTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:4)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:5)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:6)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:7)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTAGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:8)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:9)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGCTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:10)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:11)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCATCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:12)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:13)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTACGTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:14)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:15)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTAGTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:16)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGCATCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:17)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATCTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:18)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGATCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:19)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:20)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTACTCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:21)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCACGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:22)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTCTACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:23)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTCAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:24)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCAGACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:25)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGACTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:26)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:27)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTACACTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:28)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:29)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:30)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGTCGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:31)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGACGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:32)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGATGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:33)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGATCGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:34)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACGAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:35)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTAGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:36)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTACGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:37)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:38)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:39)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGCTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQID NO:40)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTCACAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:41)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACTGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:42)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCAGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:43)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGACTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:44)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTCAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:45)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTCGAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:46)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGCACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:47)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTAGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:48)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACGTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:49)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGCTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:50)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTACAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:51)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCATCTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:52)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:53)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTACGTCAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:54)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATGCTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:55)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTAGTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:56)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGCATCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:57)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCATCTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:58)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGATCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:59)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCACTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:60)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTACTCGAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:61)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCACGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:62)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTCTACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:63)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTCAGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:64)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCAGACATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:65)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGACTCAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:66)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACAGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:67)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTACACTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:68)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAGTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:69)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTGATATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:70)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGTCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:71)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGACGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:72)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGATGTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:73)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGATCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:74)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACGAGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:75)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTAGAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:76)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTACGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:77)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCGTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:78)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCATATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:79)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGCTAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:80)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCAGACGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:81)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGACTCAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:82)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACAGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:83)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTACACTGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:84)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAGTAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:85)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTGATGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:86)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGTCGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:87)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATGACGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:88)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGATGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:89)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGATCGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:90)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACGAGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:91)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTAGAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:92)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTACGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:93)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATCGTGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:94)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCATGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:95)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGCTAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(SEQ ID NO:96)
该核酸纯化模块包括纯化用超顺磁性磁珠；
该双链cDNA合成模块包括：双链合成Buffer(10X)、双链合成Enzyme Mix；
双链合成Buffer(10X):200mM Tris-HCl,120mM(NH4)2SO4,50mM MgCl2,1.6mM b-NAD,1.9mM dNTPs each,pH 7.4；
双链合成Enzyme Mix:6,000units/ml DNA Polymerase I(E.coli)5,000units/mlRNaseH,25,000units/ml E.coli DNA Ligase,10mM Tris-HCl(pH 7.5),50mM KCl,1mMDTT,0.1mM EDTA，50％glycerol；
该测序文库构建模块包括片段化酶Mix、中和Buffer、引物1，引物2、PCR Mix；其中：
片段化酶Mix：Nextera XT(Illumina)试剂盒中的Tagment DNA Buffer和Amplification Tagment Mix的混合物；
中和Buffer：Nextera XT(Illumina)试剂盒中的NT Buffer；
引物1:
序列为5’-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACG-3’(SEQ ID NO:97)，浓度为5μM；
引物2:
含12种不同标签的引物，浓度为5μM：
5’-CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTCTCGTGGGCTCGG-3’(SEQ ID NO:98)
5’-CAAGCAGAAGACGGCATACGAGATCTAGTACGGTCTCGTGGGCTCGG-3’(SEQ ID NO:99)
5’-CAAGCAGAAGACGGCATACGAGATTTCTGCCTGTCTCGTGGGCTCGG-3’(SEQ ID NO:100)
5’-CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTCTCGTGGGCTCGG-3’(SEQ ID NO:101)
5’-CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTCTCGTGGGCTCGG-3’(SEQ ID NO:102)
5’-CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG-3’(SEQ ID NO:103)
5’-CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTCTCGTGGGCTCGG-3’(SEQ ID NO:104)
5’-CAAGCAGAAGACGGCATACGAGATCCTCTCTGGTCTCGTGGGCTCGG-3’(SEQ ID NO:105)
5’-CAAGCAGAAGACGGCATACGAGATAGCGTAGCGTCTCGTGGGCTCGG-3’(SEQ ID NO:106)
5’-CAAGCAGAAGACGGCATACGAGATCAGCCTCGGTCTCGTGGGCTCGG-3’(SEQ ID NO:107)
5’-CAAGCAGAAGACGGCATACGAGATTGCCTCTTGTCTCGTGGGCTCGG-3’(SEQ ID NO:108)
5’-CAAGCAGAAGACGGCATACGAGATTCCTCTACGTCTCGTGGGCTCGG-3’(SEQ ID NO:109)
PCR Mix：166.5mM KCl，33.3mM Tris-HCl(pH 8.3)，6.66mM MgCl2，1mM dNTP,0.5U高保真DNA Polymerase。
2.权利要求1所述的高通量基因表达谱检测试剂盒在高通量基因表达谱检测中的应用。
CN201811280846.XA 2018-10-30 2018-10-30 一种高通量基因表达谱检测试剂盒 Pending CN111118112A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811280846.XA CN111118112A (zh) 2018-10-30 2018-10-30 一种高通量基因表达谱检测试剂盒

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811280846.XA CN111118112A (zh) 2018-10-30 2018-10-30 一种高通量基因表达谱检测试剂盒

Publications (1)

Publication Number Publication Date
CN111118112A true CN111118112A (zh) 2020-05-08

Family

ID=70484715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811280846.XA Pending CN111118112A (zh) 2018-10-30 2018-10-30 一种高通量基因表达谱检测试剂盒

Country Status (1)

Country Link
CN (1) CN111118112A (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090620A1 (en) * 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
CN104894271A (zh) * 2015-06-10 2015-09-09 天津诺禾致源生物信息科技有限公司 一种检测基因融合的方法及装置
CN107368706A (zh) * 2017-06-27 2017-11-21 中国水稻研究所 测序数据结果分析方法和装置、测序文库构建和测序方法
CN107502607A (zh) * 2017-06-20 2017-12-22 浙江大学 一种大量组织、细胞样本mRNA的分子条形码标记、文库构建、测序的方法
CN108277267A (zh) * 2016-12-29 2018-07-13 安诺优达基因科技(北京)有限公司 检测基因突变的装置和用于对孕妇和胎儿的基因型进行分型的试剂盒
CN108504650A (zh) * 2017-02-27 2018-09-07 云南淘谜生物科技有限公司 用于单细胞转录组测序文库构建的试剂盒及文库构建方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090620A1 (en) * 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
CN104894271A (zh) * 2015-06-10 2015-09-09 天津诺禾致源生物信息科技有限公司 一种检测基因融合的方法及装置
CN108277267A (zh) * 2016-12-29 2018-07-13 安诺优达基因科技(北京)有限公司 检测基因突变的装置和用于对孕妇和胎儿的基因型进行分型的试剂盒
CN108504650A (zh) * 2017-02-27 2018-09-07 云南淘谜生物科技有限公司 用于单细胞转录组测序文库构建的试剂盒及文库构建方法
CN107502607A (zh) * 2017-06-20 2017-12-22 浙江大学 一种大量组织、细胞样本mRNA的分子条形码标记、文库构建、测序的方法
CN107368706A (zh) * 2017-06-27 2017-11-21 中国水稻研究所 测序数据结果分析方法和装置、测序文库构建和测序方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ILLUMINA: "Illumina Adapter Sequences", 《ILLUMINA ADAPTER SEQUENCES》 *

Similar Documents

Publication Publication Date Title
CN113166797B (zh) 基于核酸酶的rna耗尽
JP5674696B2 (ja) 遠隔サンプル由来のｄｎａ断片を提供する方法
EP2714938B1 (en) Methods of amplifying whole genome of a single cell
CA3062174A1 (en) Universal short adapters for indexing of polynucleotide samples
JP2020522243A (ja) 核酸のマルチプレックス末端タギング増幅
CA3220983A1 (en) Optimal index sequences for multiplex massively parallel sequencing
US20200010880A1 (en) Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin, and related methods of use
US20230056763A1 (en) Methods of targeted sequencing
CN107893260A (zh) 高效去除核糖体rna的构建转录组测序文库的方法及试剂盒
US11441169B2 (en) Methods of small-RNA transcriptome sequencing and applications thereof
US20220356461A1 (en) High-throughput single-cell libraries and methods of making and of using
CN113322523A (zh) Rna快速建库方法及其应用
Strom Fundamentals of RNA analysis on biobanked specimens
CN114875118B (zh) 确定细胞谱系的方法、试剂盒和装置
CN111118112A (zh) 一种高通量基因表达谱检测试剂盒
CN108315320A (zh) 一种rna高通量测序文库的制备方法
CN114774514B (zh) 一种适用于高通量靶向基因组甲基化检测的文库构建方法及其试剂盒
US20240052412A1 (en) Method for detecting rna structure at whole transcriptome level and use thereof
WO2019045803A1 (en) RNA SEQUENCING METHODS
US20220380755A1 (en) De-novo k-mer associations between molecular states
CN108315824A (zh) 一种rna高通量测序文库的构建方法
US20230122979A1 (en) Methods of sample normalization
CN114438168A (zh) 一种全转录组水平rna结构检测方法及其应用
Kuut Using RNA barcoding and sequencing to study cellular differentiation on a single-cell and population level
CN117247993A (zh) 检测mRNA加帽效率的前处理方法、试剂盒及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200508

RJ01 Rejection of invention patent application after publication